Drug Trial Radar · NCT02096354
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
May 2014
Primary completion
Apr 13, 2018
Study completion Oct 8, 2020
Sponsor
- Lead sponsor
- EpicentRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 26, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This two-stage study is designed to compare the safety and activity between RRx-001 against regorafenib followed by irinotecan-based therapies in a parallel comparative study. Patients who are suffering from advanced or metastatic (meaning the disease has spread) colorectal cancer are invited to participate in this study. There will be two groups of patients (Randomized, open label study), one of these will receive RRx-001 and the other one will receive regorafenib. If patients qualify to participate in this study, they will be randomly assigned to the 'interventional arm' where patients will receive the experimental drug, RRx-001, or the 'control arm' where they will receive the current standard-of-care, Regorafenib. Patients have a 66% chance (2 out of 3) of receiving RRx-001 and a 33 % chance (1 out of 3) of receiving regorafenib. On progression in the first part of the study, provided ECOG performance status is adequate, and if clinically appropriate i.e. there are no absolute or relative contraindications in the opinion of the Investigator, all subjects will enter the second part of the study and receive irinotecan plus bevacizumab. Whether patients are given RRx-001 or regorafenib, they will also receive best supportive care, which includes treatments to help manage side effects and symptoms of cancer. This is an open label study, which means patients will know to which of these treatments, RRx-001 or regorafenib, they are assigned.
Conditions
- Colorectal Neoplasms
Interventions
RRx-001Drug
RegorafenibDrug
IrinotecanDrug
To be dosed after RRx-001 or regorafenib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From date of enrollment until death or censorship.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
UCSD Moores Cancer Center
La Jolla, California
Stanford University
Stanford, California
Kaiser Permanete
Honolulu, Hawaii
Walter Reed National Military Medical Center
Bethesda, Maryland
Aquilino Cancer Center, Maryland Oncology and Hematology PA
Rockville, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.